|
SAP30L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.65067959301268E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.54081217071689E-14 |
| Normal-vs-Stage2 |
5.02849994976629E-09 |
| Normal-vs-Stage3 |
4.77395900588817E-15 |
| Normal-vs-Stage4 |
1.63491442606301E-12 |
| Stage1-vs-Stage2 |
2.490200E-01 |
| Stage1-vs-Stage3 |
2.252400E-01 |
| Stage1-vs-Stage4 |
2.543400E-01 |
| Stage2-vs-Stage3 |
7.804500E-02 |
| Stage2-vs-Stage4 |
8.296100E-02 |
| Stage3-vs-Stage4 |
8.576800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.63824509513688E-12 |
| Normal-vs-AfricanAmerican |
5.3420000001303E-07 |
| Normal-vs-Asian |
6.88427093109567E-12 |
| Caucasian-vs-AfricanAmerican |
2.238600E-01 |
| Caucasian-vs-Asian |
5.615400E-01 |
| AfricanAmerican-vs-Asian |
4.746200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.87627691161651E-14 |
| Normal-vs-Female |
3.93018950717305E-14 |
| Male-vs-Female |
5.771400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.11972669919669E-14 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.98618899105441E-12 |
| Normal-vs-Age(81-100Yrs) |
2.37619999999827E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.979800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.788200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.387400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.855400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.717800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.736800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.955200E-03 |
| Classical-VS-Follicular |
5.297800E-02 |
| Classical-VS-Other |
1.629000E-01 |
| Classical-VS-Normal |
3.16735526695311E-12 |
| Tall-VS-Follicular |
2.257400E-01 |
| Tall-VS-Other |
9.852800E-01 |
| Tall-VS-Normal |
2.63122856836162E-14 |
| Follicular-VS-Other |
5.160200E-01 |
| Follicular-VS-Normal |
1.62492241884138E-12 |
| Other-VS-Normal |
8.49150000000742E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.62481139653892E-12 |
| N0-vs-N1 |
1.466240E-02 |
|
|
